Duta-101

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameDuta-101

Drug Alias NameBispecific Fab Fragment Antibody (DutaMab) (Dutalys)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionPlatelet-derived growth factor receptor inhibitorsVascular endothelial growth factor receptor antagonists

TargetsPlatelet-derived growth factor receptorVascular endothelial growth factor receptor

Therapy Area/IndicationsEye Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustria

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesDutalys Gmbh

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesDutalys Gmbh

Active IndicationsN/A

Inactive IndicationsEye Diseases

Other Information

ATC CodeN/A